Sucanon®…Diabetes is not curable but is treatable…enjoy life™


Sucanon®…Diabetes is not curable but is treatable…enjoy life™

 What is Sucanon®?

Sucanon® is one of only several drugs approved in the world, belonging to a class of diabetic medications called insulin sensitizers.  Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver’s sensitivity to insulin.  Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars.

1. Insulin binding to receptors and entering the cell, (which is impeded in NIDDM patients), is essential for the uptake of glucose 2. Sucanon® increases the binding of insulin to its receptors 3. Sucanon® increases the internalization of insulin 4. As a result, Sucanon® increases the intracellular level of insulin, which then increases the uptake of glucose.

Sucanon®  is a medication that helps the body make better use of its own insulin, the hormone that controls blood sugar levels.  Type II Diabetics produce insulin, but their cells gradually lose the ability to absorb and use insulin, to get sugar out of the blood stream.  Sucanon®  transports sugar out of the blood stream and into cells where it can be burned.  Sucanon®  particularly helps muscle cells use insulin and thus draw sugar out of the blood stream.

Sucanon® increases sensitivity to insulin which leads to decreased blood sugar levels and a reduction of a wide range of Type II Diabetes symptoms,  including: weight gain, fatigue, excess thirst and excess urination.  The reduction in blood sugar levels also reduces the possibility of peripheral nerve damage; the damage caused to peripheral nerves by chronic high blood sugar can ultimately lead to impotence in men and amputation of limbs in both men and women.

Diabetes:

  Diabetes is a condition in which a person has a high blood sugar (glucose) level, either because the body do not produce enough insulin, or because body cells do not properly respond to the insulin that is produced. Insulin is a hormone produced in the pancreas which regulates glucose. Insulin enables body cells to absorb glucose and to convert it into turn into energy. If the body cells do not absorb the glucose, the glucose accumulates in the blood (hyperglycemia), leading to vascular, nerve, and other complications.

There are many types of diabetes the most common of which are:

Type I Diabetes (previously called insulin-dependent diabetes mellitus (IDDM) or juvenile-onset diabetes): results from the body’s failure to produce insulin, and presently requires the person to inject insulin.

  • Type II Diabetes (previously called non-insulin-dependent diabetes mellitus (NIDDM) or maturity-onset diabetes): results from insulin resistance, a condition in which cells fail to use insulin properly, sometimes combined with an absolute insulin deficiency.

PharmaRoth Labs, Inc. Announces Mexican Distributor Surpasses Sales Goal

Media Advertising Increases as Sales Growth Exceeds Contractual Obligation

LAS VEGAS, NV–(Marketwired – Apr 16, 2014) –

PharmaRoth Labs, Inc. (OTC Pink: ROTH) (PINKSHEETS: ROTH), the exclusive producer, marketer & distributor of Sucanon®, an oral Type-II Diabetes treatment, announced today that Marcas de Renombre (MDR), the company’s exclusive distributor in Mexico has surpassed their first year minimum sales goal. In addition, the company is pleased to confirm that media advertising in Mexico is concurrently increasing.

“I am very excited to announce that our distributor in Mexico has exceeded the contractual obligation of $480,000 of purchased product this quickly,” said Luis Lopez, CEO of PharmaRoth. “The Agreement called for this minimum to be bought in the initial year in order to maintain exclusive status. The sales are media driven and even though the approval for the advertising from the Ministry took much longer than anticipated, sales has been accelerated now that the budget from MDR towards Sucanon® has been increased to meet the demand.”

Lopez continues: “As previously announced, our proprietary Type II Diabetes drug is being sold thru retail and wholesale channels backed by aggressive media advertising all throughout Mexico. The product has never enjoyed this level of availability in any market before so it is hugely exciting to be able to provide a safe and effective drug for those afflicted with such a serious disease.”

For further information regarding Sucanon®, please visit PharmaRoth Labs, Inc. website at: www.pharmaroth.com

About PharmaRoth:

PharmaRoth Labs, Inc. (OTC: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver’s sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth’s strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.

For more information: http://www.marketwired.com/AdvancedSearch/AdvancedSearchResults.aspx?sid=6e9d62e5-78f7-4fdf-b182-2f9db9e3f802

Disclaimer/ Disclosure: The Investors News Magazine is a third party publisher of news and research as well as creates original content as a news source. Original content created by Investors News Magazine is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site may be compensated by featured companies for news submissions and content marketing. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s